Fortis Overcharged Dengue Patient’s Family as High as 1700%: NPPA

Fortis charged a margin of up to 1,737 per cent on procurement price on a three-way stop cock, the regulator said.

Fortis Gurgaon, charged a margin of up to 1,737 percent on procurement price on a three-way stop cock, the regulator said.

(Photo: Liju Joseph/The Quint)

Fortis hospital at Gurgaon charged as high as 1,700 percent margin on consumables and medicines used for the treatment of a dengue patient who subsequently died of the illness, the National Pharmaceutical Pricing Authority (NPPA) said on Friday.

Fortis Memorial Research Institute, Gurgaon, charged a margin of up to 1,737 percent on procurement price on a three-way stop cock, the regulator said.

The procurement price of the consumable per unit stood at Rs 5.77 while the hospital charged Rs 106 per unit for the product, it added. The consumables listed by the NPPA included items such as syringes, gloves and towels among others.

Last month, the NPPA had asked Fortis Healthcare to provide copies of bills in relation to allegations that its Gurgaon-based hospital overcharged the family of a seven-year old girl, who died of dengue.

(Source: NPPA)

Regarding the non-scheduled formulations, NPPA said the hospital charged the family a margin as high as 914 percent. Elaborating, the NPPA said the hospital charged Rs 287.50 for Dotamin 200 mg whose procurement price per unit stood at Rs 28.35, a margin of 914 percent.

Fortis also charged Rs 3,112.50 for Merocrit 1 GM thus charging a margin of 670 percent. The hospital had procured the formulation at Rs 404.32 per unit, the regulator said. Regarding the scheduled formulations which are under the ambit of price control, the NPPA said the hospital charged up to 343 percent from the family of Adya.

The per unit procurement price of Tranemic by the hospital stood at Rs 15.75 while it was billed at Rs 69.77 per unit to the family. The regulator gave a list of 39 scheduled formulations, 41 non-scheduled formulations and 96 consumables that were used for the treatment of Adya.

"NPPA shall be taking necessary follow up action as per existing law and with in its jurisdiction," the regulator said.

The drug authority's action came after the Union Health Ministry asked all states to issue strict warnings and take action against hospitals, including private ones, which indulge in malpractices such as overcharging and do not follow standard treatment protocols.

After the report was made public, Rajiv Nath, Forum Coordinator, AiMeD said that the issue of overpricing by suppliers is not being taken seriously by the government and that it often ends up not benefiting the end consumer.

The Hospitals  negotiate hard with suppliers for favourable discounts but regretfully our discounted prices don’t benefit end users/consumers 

Rajiv Nath, Forum Coordinator, AiMeD

Nath suggested that the hospitals bring in an ethical code and consumers get 5 important issues looked at-

1. Choice of Brand
2. Choice of Procurement outside hospitals
3. Voluntary Discount on MRP - (MRP is maximum selling price and Hospitals can sell below that price. )
4. Government steps in to put a cap on Trade Margins as had been recommended by AiMeD to reasonable levels.
5. Hospitals stop cross subsidising other healthcare delivery costs from medical Consumables and brings in realistic procedure and healthcare delivery costs in a transparent manner to earn trust of their clients.

“We are interested in Systemic Correction and not witch hunting and have been highlighting this malady infecting our healthcare system for many years – problem is Government does not Act and when it does regulate it seems to be an overkill at times (We) encourage ethical manufacturers, Ethical Traders and Ethical Healthcare Providers," said Nath

(With inputs from PTI)

(Breathe In, Breathe Out: Are you finding it tough to breathe polluted air? Join hands with FIT in partnership with #MyRightToBreathe to find a solution to pollution. Send in your suggestions to [e-mail] or WhatsApp @ [phone])